Abstract:Most of the therapeutic antibodies approved for clinical use are full-size IgG1 molecules. The interaction of the IgG1 Fc with the neonatal Fc receptor (FcRn) plays a critical role in maintaining their long half-life. We have hypothesized that isolated Fc domains could be engineered to functionally mimic full-size IgG1 (nanoantibodies) but with decreased (10-fold) size. Here, we report for the first time the successful generation of a soluble, monomeric CH3 domain (mCH3). In contrast to the wild-type dimeric CH3, the mCH3 exhibited pH-dependent binding to FcRn similar to that of Fc. The binding free energy of mCH3 to FcRn was higher than that of isolated CH2 but lower than that of Fc. Therefore, CH3 may contribute a larger portion of the free energy of binding to FcRn than CH2. A fusion protein of mCH3 with an engineered antibody domain (m36.4) also bound to FcRn in a pH-dependent fashion and exhibited significantly higher neutralizing activity against HIV-1 than m36.4-Fc fusion proteins. The m36.4-mCH3 fusion protein was monomeric, stable, soluble, and expressed at a high level in Escherichia coli. We also found that engineering an additional disulfide bond in mCH3 remarkably increased its thermal stability, whereas the FcRn binding was not affected. These data suggest that mCH3 could not only help in the exploration of the dual mechanisms of the CH3 contribution to Fc functions (dimerization and FcRn interactions) but could also be used for the development of candidate therapeutics with optimized half-life, enhanced tissue penetration, access to sterically restricted binding sites, and increased therapeutic efficacy.Background: The CH3 domain of an antibody is a homodimer.Results: Soluble monomeric IgG1 CH3 (mCH3) exhibits pH-dependent binding to FcRn.Conclusion: The mCH3 can be used as a new scaffold for generation of binders with potentially enhanced half-life.Significance: The mCH3 is a promising fusion partner for therapeutic proteins with increased therapeutic efficacy. Most of the therapeutic antibodies approved for clinical use are full-size IgG1 molecules. The interaction of the IgG1 Fc with the neonatal Fc receptor (FcRn) plays a critical role in maintaining their long half-life. We have hypothesized that isolated Fc domains could be engineered to functionally mimic full-size IgG1 (nanoantibodies) but with decreased (10-fold) size. Here, we report for the first time the successful generation of a soluble, monomeric CH3 domain (mCH3). In contrast to the wild-type dimeric CH3, the mCH3 exhibited pH-dependent binding to FcRn similar to that of Fc. The binding free energy of mCH3 to FcRn was higher than that of isolated CH2 but lower than that of Fc. Therefore, CH3 may contribute a larger portion of the free energy of binding to FcRn than CH2. A fusion protein of mCH3 with an engineered antibody domain (m36.4) also bound to FcRn in a pH-dependent fashion and exhibited significantly higher neutralizing activity against HIV-1 than m36.4-Fc fusion proteins. The m36.4-mCH3 fusion protein was monomeric, stable, soluble, and expressed at a high level in Escherichia coli. We also found that engineering an additional disulfide bond in mCH3 remarkably increased its thermal stability, whereas the FcRn binding was not affected. These data suggest that mCH3 could not only help in the exploration of the dual mechanisms of the CH3 contribution to Fc functions (dimerization and FcRn interactions) but could also be used for the development of candidate therapeutics with optimized half-life, enhanced tissue penetration, access to sterically restricted binding sites, and increased therapeutic efficacy. Background: The CH3 domain of an antibody is a homodimer. Results: Soluble monomeric IgG1 CH3 (mCH3) exhibits pH-dependent binding to FcRn. Conclusion: The mCH3 can be used as a new scaffold for generation of binders with potentially enhanced half-life. Significance: The mCH3 is a promising fusion partner for therapeutic proteins with increased therapeutic efficacy.

1 Soluble Monomeric IgG 1

Soluble Monomeric IgG1 Fc

Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding

Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.

Engineered Soluble Monomeric IgG1 CH3 Domain

Interactions of IgG1 CH2 and CH3 Domains with FcRn.

Monomeric IgG1 Fc Molecules Displaying Unique Fc Receptor Interactions That Are Exploitable to Treat Inflammation-Mediated Diseases.

Structural Insights into Immunoglobulin M

Engineered Fc Based Antibody Domains and Fragments As Novel Scaffolds.

Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0.

Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use

Construction and Expression of a Human/mouse Chimeric CD19 Monoclonal Antibody: Successful Modification of a Murine IgM to a Chimeric IgG.

Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors

Glycan-independent Binding and Internalization of Human IgM to FCMR, Its Cognate Cellular Receptor

Fc engineering by monoclonal mammalian cell display for improved affinity and selectivity towards FcγRs

Single Chain Antibody Fragments with Ph Dependent Binding to FcRn Enabled Prolonged Circulation of Therapeutic Peptide in Vivo.

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria

Identification and Characterization of Novel Fc-Binding Heptapeptides from Experiments and Simulations

Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human FCGRT transgenic mice

N-terminal Truncation of an Isolated Human IgG1 CH2 Domain Significantly Increases Its Stability and Aggregation Resistance.

Function-structure approach reveals novel insights on the interplay of Immunoglobulin G 1 proteoforms and Fc gamma receptor IIa allotypes